Ignite Creation Date:
2024-05-05 @ 5:09 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00396240
Status:
WITHDRAWN
Last Update Posted:
2009-03-26
First Post:
2006-11-03
Brief Title:
ORBITAL Open-Label Primary Care Study Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
ORBITAL Open-Label Primary Care Study Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals
Status:
WITHDRAWN
Status Verified Date:
2009-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
study cancelled prior to FSI
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
24 week open label study to compare the treatment either with rosuvastatin or rosuvastatin plus initiatives to improve compliance If the subject does not reach the EAS LDL-C treatment goal at week 12 rosuvastatin will be titrated from 10mg to 20mg
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ORBITAL | None | None | None |